FAQ

Anti-ErbB3 Monoclonal Antibody KTN3379

Known as: KTN3379 
A monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Anti-ErbB3… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
01220152017

Related topics

Related topics

1 relation
antigen binding

Related mentions per year

Related mentions per year

1957-2018
1960198020002020
Anti-ErbB3 Monoclonal Antibody KTN3379
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.
Purpose: Human papillomavirus (HPV) 16 plays an etiologic role in a growing subset of head and neck squamous cell carcinomas… (More)
Is this relevant?
2017
2017
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
Head and neck squamous cell carcinoma (HNSCC) accounts for 3-5% of all tumor types and remains an unmet medical need with only… (More)
Is this relevant?
2016
2016
A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
HER3/ERBB3 is a kinase-deficient member of the EGFR family receptor tyrosine kinases (RTK) that is broadly expressed and… (More)
Is this relevant?
2016
2016
Effect of treatment of rectal cancer metastasis with intravitreal bevacizumab (Avastin) in patient with subretinal fluid and macular oedema: short-term follow-up.
We describe the management of subretinal fluid and macular oedema due to colorectal cancer metastasis to the choroid using… (More)
Is this relevant?
2015
2015
Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration.
ErbB3 (HER3) is a member of the EGF receptor (EGFR) family of receptor tyrosine kinases, which, unlike the other three family… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?